{"product_id":"dexcom-marketing-mix","title":"DexCom Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDexCom’s marketing mix blends innovative CGM product design, premium-value pricing, targeted healthcare channel distribution, and patient-focused promotion to lead the diabetes care market; this preview highlights key tactics and competitive strengths. Go beyond the summary—purchase the full 4Ps Marketing Mix Analysis for an editable, presentation-ready deep dive with real-world data, strategic insights, and practical templates to save hours of work and drive smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 CGM System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Dexcom G7 CGM System remained Dexcom's flagship wearable sensor in late 2025, with a 60-minute warm-up and a 60% smaller footprint versus G6, supporting 5‑minute real‑time glucose reads to phones or receivers and eliminating routine fingersticks for most users.\u003c\/p\u003e\n\u003cp\u003eEngineered for Type 1 and insulin‑intensive Type 2 patients, G7 delivers predictive hypoglycemia\/hyperglycemia alerts; as of Q3 2025 Dexcom reported ~3.1 million global active users and G7 adoption driving 18% year‑over‑year revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Stelo Glucose Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStelo is the first FDA-cleared OTC glucose biosensor for adults with Type 2 diabetes not on insulin, targeting metabolic health and lifestyle management by showing real-time diet and exercise impacts on glucose.\u003c\/p\u003e\n\u003cp\u003eBy removing prescription barriers, Dexcom opens access to ~90 million US adults with prediabetes\/Type 2 (CDC 2022) and expands addressable market; Dexcom reported $3.4B revenue in FY2024, positioning Stelo to drive consumer growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom ONE+ Global Solution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom ONE+ Global Solution adapts the G7’s high-accuracy sensor to a simplified app and workflow for broader Type 2 users and markets without pump integration, lowering development and support costs by an estimated 20% versus full G7 deployments.\u003c\/p\u003e\n\u003cp\u003ePriced to compete in price-sensitive Europe and Asia, ONE+ targets a larger addressable market—Dexcom estimates 2025 treatable population expansion of ~30% in those regions—helping grow international revenue where ASPs (average selling prices) sit 25–40% below US CGM pricing.\u003c\/p\u003e\n\u003cp\u003eBy streamlining software, Dexcom reduces time-to-market per country (regulatory and localization) by about 3–6 months, supporting margin-preserving volume growth and lowering customer acquisition costs for Type 2 segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Ecosystem and Clarity Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Clarity software platform is the digital core of Dexcom’s product mix, offering advanced data visualization and retrospective analysis that 1.5M users accessed in 2024 to improve glucose control.\u003c\/p\u003e\n\u003cp\u003ePatients can share comprehensive glucose reports directly with healthcare providers, reducing clinical review time by an estimated 20% and supporting tighter Time-in-Range targets.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, Clarity includes AI-driven predictive insights that forecast glucose trends up to 60 minutes ahead with published model accuracy \u0026gt;85%, aiding proactive therapy adjustments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.5M users (2024)\u003c\/li\u003e\n\u003cli\u003e~20% faster clinical review\u003c\/li\u003e\n\u003cli\u003eAI predicts 60 min ahead\u003c\/li\u003e\n\u003cli\u003eModel accuracy \u0026gt;85% (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Insulin Delivery Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom sustains a competitive edge by integrating G6\/G7 sensors with insulin pumps and smart pens, creating an automated insulin delivery (AID) ecosystem that expanded partner integrations 28% in 2024.\u003c\/p\u003e\n\u003cp\u003eThe sensor acts as the 'eyes' for pumps like Tandem t:slim X2 and Insulet Omnipod 5, enabling automated dose adjustments that cut hypo events by ~40% in pivotal trials.\u003c\/p\u003e\n\u003cp\u003eThese technical partnerships convert the standalone sensor into a core therapeutic component, supporting Dexcom’s recurring revenue—sensor revenue grew 22% year-over-year in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% more partner integrations in 2024\u003c\/li\u003e\n\u003cli\u003e~40% reduction in hypoglycemia in trials\u003c\/li\u003e\n\u003cli\u003e22% sensor revenue growth YoY 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 growth: 3.1M users, +18% revenue, rising OTC \u0026amp; sensor recurring sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom’s product line centers on the G7 CGM—60% smaller than G6, 5‑min reads, ~3.1M active users (Q3 2025), driving 18% YoY revenue growth—and new mainstream offerings: OTC Stelo for non‑insulin Type 2, ONE+ for price‑sensitive markets (expanding treatable population ~30% in 2025). Clarity analytics (1.5M users 2024) and AID integrations (28% more partners 2024) support recurring sensor revenue (+22% YoY 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 users (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e3.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 rev\u003c\/td\u003e\n\u003ctd\u003e$3.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor rev growth 2024\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner integrations 2024\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into DexCom’s Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers needing a clear breakdown of DexCom’s market positioning using real practices and competitive context, with structured, editable content ready for reports, presentations, or strategic benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses DexCom's 4P marketing insights into a concise, leadership-ready snapshot that highlights how product innovation, pricing, placement, and promotion relieve patient and provider pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Channel Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom shifted ~70% of sensor volume from durable medical equipment to retail pharmacy by 2024, so patients can pick up sensors at CVS or Walgreens like regular prescriptions.\u003c\/p\u003e\n\u003cp\u003eThis pharmacy placement cut prior authorization and billing steps, lowering provider admin time and boosting refill adherence; retail Rx rollout correlated with a ~15% increase in monthly active users in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Online Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexCom runs a direct-to-consumer e-commerce site selling sensors, transmitters, and accessories; in 2025 online sales accounted for roughly 18% of U.S. revenue (company estimate) and grew ~22% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe Stelo line sells through a dedicated web store without a doctor visit, driving faster conversion; Stelo represented ~6% of device unit volume in 2025 Q1.\u003c\/p\u003e\n\u003cp\u003eOnline fulfillment supports recurring subscribers with home delivery and auto-ship; subscription retention for e-commerce customers is about 78% annually, reducing churn and logistics variability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Specialized Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom uses a hybrid international go-to-market: direct sales teams in major markets plus third-party specialized medical distributors that navigate local regulation and reimbursement, accelerating market entry and reducing fixed costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Health Storefronts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexCom’s move into retail and health storefronts via OTC launches raised physical visibility beyond endocrinology clinics, reaching walk-in wellness shoppers and non-insulin users; retail SKU rollouts began in 2024 and expanded to 5,000+ US stores by Q4 2025.\u003c\/p\u003e\n\u003cp\u003eRetail placement helps capture the $48B US metabolic wellness market (2025 estimate) and drove a 14% channel revenue mix for DexCom in FY2025, widening trial among prevention-focused consumers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5,000+ US retail locations (Q4 2025)\u003c\/li\u003e\n\u003cli\u003e14% channel revenue share (FY2025)\u003c\/li\u003e\n\u003cli\u003e$48B US metabolic wellness market (2025 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealthcare providers drive Dexcom adoption by using Pro sample kits and clinic-based diagnostic programs; in 2024 Dexcom reported clinician-placed Pro devices accounted for a meaningful share of new prescriptions, with trials converting to long-term users at rates industry sources peg near 30–40%.\u003c\/p\u003e\n\u003cp\u003ePlacing Pro systems in clinics lets doctors fit sensors for short-term glucose evaluation, creating a referral pipeline where temporary medical use often becomes patient-owned therapy, supporting Dexcom’s recurring-revenue model—US CGM market share ~70% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician trials convert ~30–40%\u003c\/li\u003e\n\u003cli\u003ePro placements drive prescriptions and recurring revenue\u003c\/li\u003e\n\u003cli\u003eUS CGM market share ~70% (2024)\u003c\/li\u003e\n\u003cli\u003eClinical placement reduces acquisition cost per patient\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexCom expands retail to 5,000+ stores, boosts DTC to 18% and holds ~70% US CGM share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom uses retail pharmacy (5,000+ US stores by Q4 2025), DTC e-commerce (18% US revenue, 22% YoY growth in 2025), clinic Pro placements (30–40% conversion), and distributor-led international channels to boost access, lower provider admin, and raise MAU (~15% lift in 2024); FY2025 retail = 14% revenue; US CGM share ~70% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS retail locations (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e5,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC revenue share (2025)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC YoY growth (2025)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic conversion\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail revenue share (FY2025)\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CGM market share (2024)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDexCom 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual DexCom 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use, no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750077247865,"sku":"dexcom-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dexcom-marketing-mix.png?v=1772221796","url":"https:\/\/growthsharematrix.com\/products\/dexcom-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}